Inactive Instrument

Highlights BG Medicine, Inc. Other OTC

Equities

BGMD

US08861T2069

Highlights

Unlock all the news: Be the first to know and act before the market!

BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015	01/16/01	CI
BG Medicine Withdraws 510(K) Premarket Notification for Proposed Additional Indication for the Bgm Galectin-3® Test	23/15/23	CI
BG Medicine, Inc. Amends License and Distribution Agreement for Galectin-3 with Abbott Laboratories	30/15/30	CI
BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	17/15/17	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15/15/15	CI
BG Medicine, Inc. Announces First Automated Test for Galectin-3 Now Available in U.S	06/15/06	CI
BGMD Seeks Acquisitions	19/15/19	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for 2015	14/15/14	CI
BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014	31/15/31	CI
BG Medicine, Inc. Announces U.S. Food and Drug Administration's 510(k) Clearance for Galectin-3 Testing	30/14/30	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014	13/14/13	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year of 2014	14/14/14	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Full Year of 2014	14/14/14	CI
BG Medicine, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013	31/14/31	CI
BG Medicine, Inc. Reports Clinical Utility of BGM Galectin-3(R) Test for Prediction of Near-Term Rehospitalization in Patients With Heart Failure	25/14/25	CI
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014	20/14/20	CI
BG Medicine, Inc. Announces the Publication of Results of Clinical Research Study	28/14/28	CI
BG Medicine, Inc. Announces Publication of Results of an Independent Multicenter Clinical Research Trial in Europe	19/13/19	CI
BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Provides Earnings Guidance for the Year Ending December 31, 2013	06/13/06	CI
BG Medicine, Inc. Announces SilverStaff Offering Galectin-3 Testing Services to its Laboratory Customers and Physicians	06/13/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BG Medicine, Inc. Other OTC

Equities

BGMD

US08861T2069

Highlights

Filters